PRostate Olaparib Real World Evidence Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorAstraZeneca
About this trial
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Eligibility criteria
Qualifiers
Adult male patients (≥ 18 years old)
with metastatic castration-resistant prostate cancer,
who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program
who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA,
Disqualifiers
Patients opposed to the collection of their data
Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov